Skip to content
HowShorted

LA JOLLA PHARMACEUTICAL CO short interest in 2018

In 2018, LA JOLLA PHARMACEUTICAL CO's disclosed short interest ran from 24.65% of shares outstanding on 12 Jan 2018 to 32.69% on 31 Dec 2018, a change of +8.04 percentage points. The year's high was 38.51% on 28 Sep 2018 and its low 24.65% on 12 Jan 2018, averaging 32.40% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 36.61 days on 13 Jul 2018. Full history: LA JOLLA PHARMACEUTICAL CO.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for LA JOLLA PHARMACEUTICAL CO in 2018

2018 in figures

Start of year
24.65% (12 Jan 2018)
End of year
32.69% (31 Dec 2018)
Change
+8.04 pp
High
38.51% (28 Sep 2018)
Low
24.65% (12 Jan 2018)
Average
32.40%
Highest days to cover
36.61 (13 Jul 2018)
SEC filings marked
7

Every report in 2018

LA JOLLA PHARMACEUTICAL CO short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201824.65%13.22
31 Jan 201826.30%12.24
15 Feb 201829.34%10.79
28 Feb 201828.85%11.4110-K filed
15 Mar 201827.12%8.64
29 Mar 201828.01%11.08
13 Apr 201829.70%11.86
30 Apr 201827.99%19.68
15 May 201830.63%16.2410-Q filed, results (8-K)
31 May 201829.75%30.87
15 Jun 201830.23%23.10
29 Jun 201831.17%24.76
13 Jul 201831.73%36.61
31 Jul 201834.93%25.79
15 Aug 201836.59%8.8710-Q filed, results (8-K)
31 Aug 201837.31%22.99
14 Sep 201837.80%25.59
28 Sep 201838.51%32.02
15 Oct 201837.33%19.91
31 Oct 201836.73%17.6710-Q filed, results (8-K)
15 Nov 201837.32%26.03
30 Nov 201836.70%32.76
14 Dec 201836.26%23.70
31 Dec 201832.69%13.95

See also: LA JOLLA PHARMACEUTICAL CO's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.